Aug 13, 2020
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
Jun 12, 2020
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jun 10, 2020
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
Jun 08, 2020
Intravacc and Versatope Sign Research Service Agreement to Develop Universal Influenza Vaccine Based on OMV technology
Jun 03, 2020
Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected
May 20, 2020
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
May 04, 2020
BiondVax Announces Upcoming Expiration of Public Warrants
Apr 28, 2020
COVID-19 Crisis Focuses Attention on Oft-Overlooked Vaccine Industry
Mar 24, 2020
New Directors Elected to BiondVax's Board of Directors
Mar 19, 2020
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
Mar 18, 2020
Versatope Selects Influenza Vaccine Candidate for Clinical Development
Mar 11, 2020
Greffex, Inc. Completes COVID-19 Vaccine and Prepares for Testing
Feb 27, 2020
Global H1N1 Vaccines Industry Insights, 2020 to 2025 - Featuring Profiles of MedImmune, Sanofi Pasteur, GlaxoSmithKline, Abbott Labs, CSL Limited, Pfizer, and More
Feb 05, 2020
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
Jan 16, 2020
BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
Nov 04, 2019
FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Oct 07, 2019
BiondVax Receives EUR4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
Sep 23, 2019
UM School Of Medicine's Center For Vaccine Development And Global Health Receives NIH Contract Of Up To More Than $200 Million For Influenza Research
Sep 12, 2019
Visiongain Report Claims There is Huge Potential Within the $4.9bn Influenza Vaccines Market
Aug 30, 2019
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response